Ann: Medibio Quarterly Update and Cashflow Report, page-35

Agree and I am quietly confident. I was very happy with Dave and his restructure but I think even he would agree : why pay top $$$ for a US CEO if the focus has changed? FDA dill on the cards but pushed out. The fact that we don’t have FDA under our belt has not stopped some pretty big companies to sign up for trials. And the reality is that at the end of the day Claude Solitario has more skin in the game than all the previous CEOs and a hugely vested interest to make things happen.. I sense we should soon see the finalisation of a few contracts which will bring value and $$$ to the company...